Covid-19 vaccines for the youngest group of children (under the age of six) may soon be available — potentially in the next month — as Moderna announced on Thursday morning that it has submitted an EUA request to the FDA.
The FDA still needs to review the application, which is based on data unveiled late last month showing a robust neutralizing antibody response in the 6 month to under 6 years age group after a two-dose series of the vaccine, along with a favorable safety profile. The FDA still needs to set up an advisory committee of outside experts to review the data.
How long that review may take is still up in the air. But the FDA’s vaccine chief Peter Marks told a Senate committee on Tuesday that a vaccine for this youngest age group is a top priority, and a schedule is coming within a week.
The FDA previously scheduled and then postponed an adcomm meeting to review Pfizer/BioNTech vaccine data on two doses for this same youngest age group, but the companies decided to pull back at the last minute without being entirely clear, as an application was not submitted and new data were not made public.
More recently, Pfizer said it’s going for a third dose and expects to release data on its vaccine in this group of infants and children before the end of the quarter, although the New York Times reported recently that application could come as soon as next month.
As far as the timeline for when these Moderna vaccines may be available, Marks also told a Senate committee on Tuesday that the FDA will be releasing plans for holding the adcomm meeting, and providing a timeline on its review within the next week.
The timing remains a big question mark and is dependent on how quickly the FDA can review the application, which typically (outside a pandemic) would take the agency six to 10 months to review, but will likely be condensed to weeks in this case. The agency may also opt to hold a joint Pfizer-Moderna VRBPAC meeting to allow its outside advisors to review all of the data together.
Paul Offit, professor of pediatrics at Children’s Hospital of Philadelphia and a member of the adcomm that would meet to discuss the Moderna and Pfizer data, told Endpoints News via email, “Nothing on the schedule until June.” But he also clarified that he didn’t know what would be discussed in June. The Moderna VRBPAC meeting may not have been scheduled yet.
If authorized, the Moderna vaccines will likely be made available at no cost to Americans as the trial on which the EUA is based was funded by the US government and conducted in collaboration with the NIH’s National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.
Moderna CEO Stéphane Bancel said in a statement, “We believe mRNA-1273 will be able to safely protect these children against SARS-CoV-2, which is so important in our continued fight against COVID-19, and will be especially welcomed by parents and caregivers.”
Similar to Pfizer, Moderna said it’s also currently studying booster doses for the two oldest pediatric cohorts, and the company is designing a study to evaluate the potential for a booster for those aged 6 months to under 6 years too.
The company said it is evaluating booster doses of the original vaccine, as well as a bivalent booster candidate, known as mRNA-1273.214, which includes both Omicron-specific mRNA and mRNA-1273. Moderna also recently unveiled promising data for another bivalent booster, known as mRNA-1273.211 and which includes mutations found in the Beta variant of concern, and which bested the company’s original booster in terms of neutralizing titers against all variants of concern, including Omicron.
The news, which follows similar results for the Pfizer/BioNTech Covid-19 vaccine when combined with Beta, bodes well for the booster season coming in the fall.senate us government pandemic covid-19 vaccine fda japan
Long COVID: female sex, older age and existing health problems increase risk – new research
A new study has analysed UK data from long-term health surveys and electronic health records to understand how common long COVID is, and who might be at…
About 2 million people in the UK currently have long COVID, according to the latest data from the Office for National Statistics.
In the UK, long COVID is defined as “signs and symptoms that continue or develop after acute COVID-19”. This definition is further split into people who have symptoms between four to 12 weeks after infection (ongoing symptomatic COVID-19) and for 12 weeks or more (post-COVID syndrome).
Symptoms can include fatigue, breathlessness, difficulty concentrating and many more – but the precise nature of the symptoms is not well understood. There are also gaps in our knowledge when it comes to the frequency of long COVID, and whether there are particular factors that put people at higher risk of developing the condition.
All of this is partly because the symptoms used to define long COVID often vary between studies, and these studies tend to be based on relatively few people. So the results may not apply to the wider population.
In a new study published in the journal Nature Communications, my colleagues and I looked at data from ten UK-based long-term studies, alongside 1.1 million anonymised electronic health records from English general practices. Based on this data, we investigated whether the burden of long COVID (how common it is) differs by demographic and health characteristics, such as age, sex and existing medical conditions.
The studies were established before the pandemic, and have tracked participants over many years. From these surveys, we used data from 6,907 people who self-reported they’d had COVID-19. Comparing this with the data from the electronic health records of people diagnosed with COVID allowed us to examine the frequency of long COVID in those who have seen their GP about it and those who haven’t.
We found that of the people who self-reported having COVID in the studies, the proportion who reported symptoms for longer than 12 weeks ranged between 7.8% and 17%, while 1.2% to 4.8% reported “debilitating” symptoms.
In the electronic health records, we found that only 0.4% of people with a COVID diagnosis were subsequently recorded as having long COVID. This low proportion of diagnoses by GPs may be partly because formal logging of long COVID was only introduced for doctors in November 2020.
The proportion of people who reported symptoms for more than 12 weeks varied by age. There was also a lot of variation depending on which definition each study used to capture long COVID. But overall, we found evidence to suggest an increased risk of long COVID was associated with increasing age up to age 70.
The studies include participants across a range of ages, from an average age of 20 to 63. Using a strict definition of symptoms affecting day-to-day function, we found that the proportion of people with symptoms for 12 or more weeks generally rose with increasing age, ranging from 1.2% for 20-year-olds to 4.8% for those aged 63.
We also found that a range of other factors is associated with a heightened risk of developing long COVID. For instance, being female, poorer pre-pandemic mental health and overall health, obesity and having asthma were also identified as risk factors in both the long-term studies and electronic health records.
These findings are broadly consistent with other emerging evidence on long COVID. For example, a recent international review study concluded that women are 22% more likely than men to experience long COVID.
It will be important to understand why these links exist, which is beyond the scope of our research. But identifying who may be at higher risk of long COVID is important, and as we continue to learn more, this could inform public health prevention and treatment strategies.
Ellen Thompson does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.treatment pandemic covid-19 uk
Redundancy: what to know about your rights when an employer lets you go
Redundancies are an unfortunate fact of life for businesses, but companies can try to make the process of job cuts less painful for workers.
One of the biggest rail strikes in 30 years has been playing out in recent weeks as 40,000 workers protest the threat of job cuts. Their employer, Network Rail, wants to lay off up to 1,800 people as it prepares to introduce new technologies in an attempt to save more than £100 million annually following a post-pandemic drop in passenger numbers.
Transport secretary Grant Shapps has claimed this industrial action will cost around £150 million in lost revenue, in addition to a £450 million hit to the wider UK economy. With such significant costs expected, not to mention the ongoing impact on individual travellers, the government has called on the parties involved – the rail operators and the unions representing the workers – to agree a deal via negotiations.
We already saw the impact of a company taking such matters into its own hands earlier this year when P&O Ferries dismissed 800 employees without notice as it tried to make savings. In the current situation, Network Rail’s management is following a process of consultation with affected employees. It has offered voluntary redundancy in an attempt to limit the impact of its plans for modernisation that will lead to the redundancies, with more than 5,000 workers applying so far, according to news reports.
Unfortunately, redundancies are a fact of life for businesses, particularly in difficult times like the current economic environment. In such circumstances, businesses often choose to make redundancies to create a more sustainable future for the company as a whole. And while making employees redundant tends to be an unpleasant experience for all parties involved, the impact is, of course, most significant for the employees that are losing their jobs. Companies must therefore find a way to implement redundancies with compassion, providing clear communication for all employees during the process, as well as offering ongoing tools and support to the employees that lose their jobs and those that remain.
So what should you expect? Employees at risk of redundancy are entitled to a fair redundancy process underpinned by the Employee Rights Act 1996, which includes the right to meaningful consultation. According to the UK Advisory, Conciliation and Arbitration Service (ACAS) this should provide the opportunity to discuss the changes and why certain employees are at risk of redundancy. If employees meet specific criteria, such as being employed for a certain amount of time (usually a minimum of two years), they are also entitled to statutory redundancy payments. It is important to check specific employment contracts and the company’s policy on redundancy pay as well, however.
Going beyond basic rights, redundancy programmes can be implemented more smoothly when employees understand the business rationale for the situation, according to my research. Business leaders must provide a clear understanding of why redundancies are being made. Network rail, for example, has discussed its plan to make savings by implementing technology such as drones for site inspections and to drive automation of ticket sales.
To ensure consultations are useful and beneficial, employers should also be able to clearly demonstrate to unions and their members how they have attempted to save costs through means other than redundancies. This could involve reducing or selling unused assets or saving on procurement costs, for example. All reasonable alternatives to redundancies should be considered, such as potential redeployment of employees at risk of redundancy.
Once it has been decided that redundancies are to be made, however, a company should be ready and able to explain how employees were selected and why certain parts of the business were impacted. Overall, employees and unions should be given a clear plan for individual and collective consultation with anticipated timelines and effective communication channels. This will show all impacted employees that careful consideration was given to all decisions around the redundancy programme.
For those employees at risk of redundancy, additional services should be provided to help with the adjustment to life after redundancy. This can include support from the company itself, as well as services from external providers for up to three months after redundancy. Examples include:
Retraining: redundancies can be avoided where possible through redeployment by retraining employees to fulfil alternative, available and suitable roles. This depends on the role requirements and reasonable ability to transfer skills.
Counselling: loss of income is extremely stressful, causing anxiety and financial worries. Organisations should have the necessary help in place to support employee’s mental health by providing access to free counselling and one-to-one support.
Transition: employers can also offer alternative support such as workshops on financial planning and guidance, or on how to start a business.
Supporting other employees
A more compassionate redundancy process should also consider the employees that remain with the organisation. During my research, I found that the way organisations treat the employees who lose their jobs can have a significant impact on the employees who remain in the organisation. They may feel guilty or angry about colleagues losing their jobs, as well as experiencing continued fear of job insecurity if more job losses are expected.
Treating all employees with compassion, fairness and respect during redundancies also benefits the management staff that must implement the process of redundancies. Again, widespread communication – not just with the union, but with employees themselves – helps companies conduct the process with compassion. Remaining employees should understand the future vision and mission of the organisation. Other ways to lift employee morale include investing in training and development, as well as recognising job-related progress or achievements.
Redundancies cannot always be avoided, but the negative impact can certainly be limited for those who lose their jobs, as well as for those who remain. And when unions work with management to ease the pain of redundancies, employees can at least leave the organisation more equipped for the future.
Madeleine Stevens does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.uk pandemic
U.S. FDA will decide on redesigned COVID vaccines by early July
U.S. regulators plan to decide by early July on whether to change the design of COVID-19 vaccines this fall in order to combat more recent variants of…
U.S. FDA will decide on redesigned COVID vaccines by early July
June 28, 2022, 9:58 AM EDT
By Michael Erman
“The better the match of the vaccines to the circulating strain we believe may correspond to improve vaccine effectiveness, and potentially to a better durability of protection,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said at a meeting of outside advisers to the regulator.
The committee is scheduled to vote on a recommendation on whether to make the change later on Tuesday.
The updated shots are likely to be redesigned to fight the Omicron variant of the coronavirus, experts say. read more The exact composition of the retooled shots and whether they also will include some of the original vaccine alongside new components will be considered at the meeting.
Pfizer Inc (PFE.N), Moderna Inc (MRNA.O) and Novavax Inc. (NVAX.O) are scheduled to present data at the meeting. All three companies have been testing versions of their vaccines updated to combat the BA.1 Omicron variant that was circulating and led to a massive surge in infections last winter.
Both Moderna and Pfizer with partner BioNTech (22UAy.DE) have said that their respective redesigned vaccines generate a better immune response against BA.1 than their current shots that were designed for the original virus that emerged from China.
They have said that their new vaccines also appear to work against the more recently circulating BA.4 and BA.5 Omicron subvariants, even though that protection is not as strong as against BA.1.
Experts also want to know if the new shots will boost protection against severe disease and death for younger, healthier people or merely offer a few months’ additional safeguard against mild infection.
Scientists who have questioned the value of booster shots for young and healthy people have said a broad campaign is not needed with an updated shot either.
Other experts have championed any additional protection new vaccines may offer.
Our Standards: The Thomson Reuters Trust Principles.
Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) Breaking Out as Biotech Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing
CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails
After a near 10% rally this week can the Netflix share price make a comeback?
The Sussex researchers who used international collaboration and 3D printing to stem PPE shortages in Nigeria
Twitter Just Fine With Assassination Threats Against Justice Clarence Thomas
40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent
Hot Penny Stocks to Buy This Week? 3 For Your List
Aura High Yield SME Fund: Letter to Investors 24 June 2022
FTSE 100 gains as commodity-linked stocks bounce back
Looking Ahead In The Macro Market—Stock Market Preview For The Week Of June 27, 2022
Economics14 hours ago
Asia businesses struggle to offset losses from increased B2B bad debt, Atradius survey reveals
Science16 hours ago
Hot Penny Stocks to Buy This Week? 3 For Your List
Spread & Containment12 hours ago
FTSE 100 gains as commodity-linked stocks bounce back
Spread & Containment23 hours ago
Consumer Spending Is Shifting: Should You Still Buy Lowe’s Stock?
Economics19 hours ago
Victor Davis Hanson: America Is More Fragile Than The Left Understands
Economics20 hours ago
Hopes of Lower Inflation Spark Market Rebound
Science24 hours ago
Rensselaer researchers receive $3.5 million grant for development of COVID antiviral drug
Economics18 hours ago
Winners and losers of this volatile housing market